Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase II, Multicenter, Open-label Study to Evaluate the Efficacy and Safety of Trastuzumab Deruxtecan (T-DXd) for the Treatment of Unresectable and/or Metastatic Solid Tumors Harboring HER2 Activating Mutations Regardless of Tumor Histology

Next Previous
X
Search
Trial Profile

A Phase II, Multicenter, Open-label Study to Evaluate the Efficacy and Safety of Trastuzumab Deruxtecan (T-DXd) for the Treatment of Unresectable and/or Metastatic Solid Tumors Harboring HER2 Activating Mutations Regardless of Tumor Histology

Status: Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 24 Dec 2024

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Trastuzumab-deruxtecan (Primary)
  • Indications Adenocarcinoma; Solid tumours
  • Focus Therapeutic Use
  • Acronyms DESTINY-PanTumor01; DPT01
  • Sponsors AstraZeneca

    • Most Recent Events

    • 22 Jan 2024 Planned End Date changed from 17 Jan 2028 to 14 Jul 2026.
    • 24 Oct 2023 Results (data cutoff Jan 25 2023) assessing the efficacy and safety of trastuzumab deruxtecan in patients with solid tumors, presented at the 48th European Society for Medical Oncology Congress.
    • 11 Oct 2023 According to an AstraZeneca media release, clinical data from this will be presented at the European Society for Medical Oncology (ESMO) Congress, October 20-24, 2023.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top